EP300 and neoplasm: CBP/p300 thereby augment T regulatory cell and myeloid-derived suppressor cell survival and function; suppress cytotoxic T cell-driven immunity, lymphocyte activation and proliferation; and promote tumor progression in vivo77-80 (Table 1).